JP2013515486A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515486A5
JP2013515486A5 JP2012546229A JP2012546229A JP2013515486A5 JP 2013515486 A5 JP2013515486 A5 JP 2013515486A5 JP 2012546229 A JP2012546229 A JP 2012546229A JP 2012546229 A JP2012546229 A JP 2012546229A JP 2013515486 A5 JP2013515486 A5 JP 2013515486A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546229A
Other languages
English (en)
Japanese (ja)
Other versions
JP6000855B2 (ja
JP2013515486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/061987 external-priority patent/WO2011079257A2/en
Publication of JP2013515486A publication Critical patent/JP2013515486A/ja
Publication of JP2013515486A5 publication Critical patent/JP2013515486A5/ja
Application granted granted Critical
Publication of JP6000855B2 publication Critical patent/JP6000855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546229A 2009-12-24 2010-12-23 ヒトアンギオポエチン様タンパク質４に対するヒト抗体 Expired - Fee Related JP6000855B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US29009209P 2009-12-24 2009-12-24
US61/290,092 2009-12-24
US30635910P 2010-02-19 2010-02-19
US61/306,359 2010-02-19
US32831610P 2010-04-27 2010-04-27
US61/328,316 2010-04-27
US34927310P 2010-05-28 2010-05-28
US61/349,273 2010-05-28
US35612610P 2010-06-18 2010-06-18
US61/356,126 2010-06-18
PCT/US2010/061987 WO2011079257A2 (en) 2009-12-24 2010-12-23 Human antibodies to human angiopoietin-like protein 4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015096446A Division JP2015145424A (ja) 2009-12-24 2015-05-11 ヒトアンギオポエチン様タンパク質４に対するヒト抗体

Publications (3)

Publication Number Publication Date
JP2013515486A JP2013515486A (ja) 2013-05-09
JP2013515486A5 true JP2013515486A5 (enExample) 2014-02-06
JP6000855B2 JP6000855B2 (ja) 2016-10-05

Family

ID=43629324

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012546229A Expired - Fee Related JP6000855B2 (ja) 2009-12-24 2010-12-23 ヒトアンギオポエチン様タンパク質４に対するヒト抗体
JP2015096446A Pending JP2015145424A (ja) 2009-12-24 2015-05-11 ヒトアンギオポエチン様タンパク質４に対するヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015096446A Pending JP2015145424A (ja) 2009-12-24 2015-05-11 ヒトアンギオポエチン様タンパク質４に対するヒト抗体

Country Status (30)

Country Link
US (2) US8354103B2 (enExample)
EP (1) EP2516466B1 (enExample)
JP (2) JP6000855B2 (enExample)
KR (1) KR101842570B1 (enExample)
CN (1) CN102741284A (enExample)
AR (1) AR079708A1 (enExample)
AU (1) AU2010336369C1 (enExample)
BR (1) BR112012017765A2 (enExample)
CA (1) CA2785158C (enExample)
CY (1) CY1118898T1 (enExample)
DK (1) DK2516466T3 (enExample)
ES (1) ES2628135T3 (enExample)
HR (1) HRP20170524T1 (enExample)
HU (1) HUE034722T2 (enExample)
IL (1) IL220402A (enExample)
JO (1) JO3274B1 (enExample)
LT (1) LT2516466T (enExample)
MX (1) MX337082B (enExample)
NZ (1) NZ600768A (enExample)
PL (1) PL2516466T3 (enExample)
PT (1) PT2516466T (enExample)
RS (1) RS56009B1 (enExample)
RU (1) RU2580045C2 (enExample)
SG (1) SG181784A1 (enExample)
SI (1) SI2516466T1 (enExample)
SM (1) SMT201700280T1 (enExample)
TW (1) TWI488643B (enExample)
UY (1) UY33144A (enExample)
WO (1) WO2011079257A2 (enExample)
ZA (1) ZA201204507B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
AU2013245630A1 (en) * 2012-04-13 2014-10-30 The Johns Hopkins University Treatment of ischemic retinopathies
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
US9868777B2 (en) 2013-06-10 2018-01-16 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
KR101538787B1 (ko) * 2013-06-27 2015-07-22 인하대학교 산학협력단 췌장염 진단용 바이오 마커 조성물
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
WO2016020882A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
SG10201805646WA (en) * 2014-08-07 2018-08-30 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
US9556225B2 (en) * 2014-10-15 2017-01-31 Uniao Quimica Farmaceutica Nacional S/A Peptide stimulator of cell survival and proliferation
US20180125816A1 (en) 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
MX382035B (es) 2016-11-17 2025-03-13 Regeneron Pharma Uso de un inhibidor angptl8 en la preparación de un medicamento para tratar la obesidad.
EP3565598A4 (en) * 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
WO2020191293A1 (en) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
AU2020339478A1 (en) 2019-08-29 2021-05-06 Remegen Co., Ltd. Anti PD-L1 antibody and use thereof
AU2020399633A1 (en) * 2019-12-09 2022-07-07 Empirico Inc. Oligonucleotides for treatment of Angiopoietin like 4 (ANGPTL4) related diseases
WO2021173753A1 (en) 2020-02-26 2021-09-02 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
JP2023533253A (ja) * 2020-07-02 2023-08-02 マブリティクス， インコーポレイテッド 細胞結合タンパク質および使用の方法
WO2022006555A2 (en) * 2020-07-02 2022-01-06 Gigagen, Inc. BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
WO2023239307A1 (en) * 2022-06-10 2023-12-14 Nanyang Technological University Methods of treating liver fibrosis, inflammation or associated diseases using an angptl4 antagonist
CN119907693A (zh) * 2022-08-02 2025-04-29 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ES2371083T3 (es) * 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
BRPI0606432A2 (pt) 2005-01-07 2009-06-30 Lexicon Pharmaceuticals Inc anticorpos monoclonais contra angptl4
DK1962895T3 (da) 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
AU2007227251A1 (en) * 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Similar Documents

Publication Publication Date Title
RU2012131547A (ru) Антитела человека против ангиопоэтин-подобного белка 4 человека
US11542325B2 (en) Anti-activin A antibodies and uses thereof
RU2013155906A (ru) Антитела анти-angptl3 и их применение
CA2698382C (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20160032014A1 (en) Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
RU2012156938A (ru) Антитела против gdf8 человека
RU2014147773A (ru) Человеческие антитела с высокой аффинностью к рецепторам il-4 человека
RU2011129316A (ru) Высокоаффинные человеческие антитела к pcsk9
JP2013542194A5 (enExample)
JP7292526B2 (ja) 操作された抗ｉｌ－２抗体
JP2018510617A5 (enExample)
WO2014150983A2 (en) Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
JP2016501892A5 (enExample)
JP2022509156A5 (enExample)
JP2015503909A5 (enExample)
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
JP2019162119A5 (enExample)
EP2766394A1 (en) Treatment for rheumatoid arthritis
CN111094339A (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
WO2014072741A1 (en) Humanised antibody and method of production thereof
EP3145544A1 (en) Ang2 antibodies
WO2021063331A1 (zh) EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
EP3532501A1 (en) Anti-rankl antibodies and uses thereof